LONDON - IXICO plc (AIM: IXI), a company specializing in medical imaging advanced analytics, has awarded 500,000 share options to Chief Scientific Officer (CSO) Robin Wolz, who is also a person discharging managerial responsibilities (PDMR) within the company. This grant is part of an incentive plan aligned with the company's executive directors, aimed at recognizing Mr. Wolz's growing contribution to IXICO's success.
The share options are subject to performance criteria based on retention and annual share price growth over a three-year period, with an exercise price of £0.01 each. The options will be held until the third anniversary of their award. The share price growth target is set at an absolute compound growth of 40% over the three-year period or a 40% growth compared to the previous year, measured by a three-month average share price leading up to each anniversary of the option award. The baseline for the first year's growth comparison is the average share price immediately before the CEO joined the company on August 19, 2024.
The company also disclosed that 200,000 options previously awarded to Mr. Wolz on October 30, 2024, have lapsed as of November 28, 2024.
Furthermore, IXICO reported that Chief Financial Officer (CFO) Grant Nash, another PDMR, has sold and immediately repurchased 260,000 ordinary shares as part of a Bed & ISA transaction on December 4, 2024. This transaction does not alter Mr. Nash's beneficial interest in the company's shares.
This announcement is based on a press release statement and provides information about the internal dealings and incentive structures for PDMR within IXICO plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.